CSO Ranga Sarangarajan, CAO Slava Akmaev explain how embrace of AI has led to promising drug candidates


October 4, 2017

CSO Ranga Sarangarajan, CAO Slava Akmaev explain how Berg’s embrace of AI has led to the development of promising drug candidates BPM 31510 and BPM-31543.

Sarangarajan notes that “AI provides an opportunity for understanding the data in avenues that a traditionally trained mind can’t. We have our biases, but AI is purely data-driven.”

Read the article. 

Recent news